How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

We independently review everything we recommend. When you buy through our links, we may earn a commission. Learn more› By Elissa Sanci Elissa Sanci is a senior writer who has reported on label makers, ...

Meet the backpack that’s beloved by thousands for its space-saving prowess. Olivia Young is a journalist and slow travel advocate. Her favorite travel days usually involve vegan food, wildlife ...

Nvidia disclosed in recent regulatory filings that it had fully exited its roughly two‑year, 7.71 million‑share investment in Recursion Pharmaceuticals, while Cathie Wood’s ARK Invest simultaneously ...

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel ...